XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Basis of Accounting Presentation and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Basis of Accounting Presentation and Summary of Significant Accounting Policies [Abstract]  
Adjustments to Financial Statement The adjustments to the financial statement items for the affected periods are as follows:
 
 
  
As Previously
Reported
    
Adjustments
    
As Restated
  
 
  
(unaudited)
  
Consolidated Balance Sheet as of December 31, 2020
                  
 
                  
In-process research and development
  
$
6,860,000
    
$
(870,000
)
  
$
5,990,000
  
Contingent consideration
  
$
20,110,000
    
$
(20,110,000
)
  
$
-
  
Accumulated deficit
  
$
(37,381,000
)
  
$
19,240,000
    
$
(18,141,000
)
 
                        
Consolidated Statement of Operations for the year ended December 31, 2020
                        
 
                        
Change in fair value of contingent consideration
  
$
19,240,000
    
$
(19,240,000
)
  
$
-
  
Net loss
  
$
(26,531,000
)
  
$
19,240,000
    
$
(7,291,000
)
Net loss per common share - basic and diluted
  
$
(1.51
)
  
$
1.10
    
$
(0.41
)
 
                        
Consolidated Statement of Cash Flows for the year ended December 31, 2020
                        
 
                        
Net loss
  
$
(26,531,000
)
  
$
19,240,000
    
$
(7,291,000
)
Change in fair value of contingent consideration
  
$
19,240,000
    
$
(19,240,000
)
  
$
-
  
 
                        
Consolidated Balance Sheet as of December 31, 2021
                        
 
                        
In-process research and development
  
$
6,860,000
    
$
(870,000
)
  
$
5,990,000
  
Security deposits and other assets
  
$
522,000
    
$
(34,000
)
  
$
488,000
  
Contingent consideration
  
$
19,930,000
    
$
(19,930,000
)
  
$
-
  
Other liabilities
  
$
23,000
    
$
25,000
    
$
48,000
  
Accumulated deficit
  
$
(159,703,000
)
  
$
19,001,000
    
$
(140,702,000
)
 
                        
Consolidated Statement of Operations for the year ended December 31, 2021
                        
 
                        
Change in fair value of contingent consideration
  
$
(180,000
)
  
$
180,000
    
$
-
  
Provision for income taxes
  
$
(5,000
)
  
$
(59,000
)
  
$
(64,000
)
Net loss
  
$
(122,306,000
)
  
$
(239,000
)
  
$
(122,545,000
)
Net loss attributable to common stockholders
  
$
(122,322,000
)
  
$
(239,000
)
  
$
(122,561,000
)
Net loss per common share - basic and diluted
  
$
(2.82
)
  
$
(0.01
)
  
$
(2.83
)
 
                        
Consolidated Statement of Cash Flows for the year ended December 31, 2021
                        
 
                        
Net loss
  
$
(122,306,000
)
  
$
(239,000
)
  
$
(122,545,000
)
Change in fair value of contingent consideration
  
$
(180,000
)
  
$
180,000
    
$
-
  
Security deposits and other assets
  
$
(34,000
)
  
$
34,000
    
$
-
  
Other liabilities
  
$
-
    
$
25,000
    
$
25,000
  
 
The adjustments to the line items for the affected unaudited quarterly financial statements are as follows:
 
 
  
As of June 30, 2020
    
As of September 30, 2020
  
 
  
As Previously
Reported
    
Adjustments
    
As Restated
    
As Previously
Reported
    
Adjustments
    
As Restated
  
 
  
(in thousands)
    
(in thousands)
  
Consolidated Balance Sheets
  
(unaudited)
    
(unaudited)
  
 
                                    
In-process research and development
  
$
6,860,000
    
$
(870,000
)
  
$
5,990,000
    
$
6,860,000
    
$
(870,000
)
  
$
5,990,000
  
Contingent consideration
  
$
870,000
    
$
(870,000
)
  
$
-
    
$
870,000
    
$
(870,000
)
  
$
-
  
 
 
  
As of March 31, 2021
    
As of June 30, 2021
  
 
  
As Previously
Reported
    
Adjustments
    
As Restated
    
As Previously
Reported
    
Adjustments
    
As Restated
  
 
  
(in thousands)
    
(in thousands)
  
Consolidated Balance Sheets
  
(unaudited)
    
(unaudited)
  
 
                                    
In-process research and development
  
$
6,860,000
    
$
(870,000
)
  
$
5,990,000
    
$
6,860,000
    
$
(870,000
)
  
$
5,990,000
  
Contingent consideration
  
$
19,290,000
    
$
(19,290,000
)
  
$
-
    
$
19,290,000
    
$
(19,290,000
)
  
$
-
  
Accumulated deficit
  
$
(55,083,000
)
  
$
18,420,000
    
$
(36,663,000
)
  
$
(65,176,000
)
  
$
18,420,000
    
$
(46,756,000
)
 
 
  
As of September 30, 2021
  
 
  
As Previously
Reported
    
Adjustments
    
As Restated
  
 
  
(in thousands)
  
Consolidated Balance Sheets
  
(unaudited)
  
 
                  
In-process research and development
  
$
6,860,000
    
$
(870,000
)
  
$
5,990,000
  
Contingent consideration
  
$
19,360,000
    
$
(19,360,000
)
  
$
-
  
Accumulated deficit
  
$
(151,232,000
)
  
$
18,490,000
    
$
(132,742,000
)
 
 
  
Three months ended March 31, 2021
    
Three months ended September 30, 2021
  
 
  
As Previously
Reported
    
Adjustments
    
As Restated
    
As Previously
Reported
    
Adjustments
    
As Restated
  
 
  
(in thousands, except per share data)
    
(in thousands, except per share data)
  
Consolidated Statement of Operations
  
(unaudited)
    
(unaudited)
  
 
                                    
Change in fair value of contingent consideration
  
$
(820,000
)
  
$
820,000
    
$
-
    
$
70,000
    
$
(70,000
)
  
$
-
  
Net loss
  
$
(17,702,000
)
  
$
(820,000
)
  
$
(18,522,000
)
  
$
(86,055,000
)
  
$
70,000
    
$
(85,985,000
)
Net loss attributable to common stockholders
  
$
(17,702,000
)
  
$
(820,000
)
  
$
(18,522,000
)
  
$
(86,055,000
)
  
$
70,000
    
$
(85,985,000
)
Net loss per common share - basic and diluted
  
$
(0.64
)
  
$
(0.03
)
  
$
(0.67
)
  
$
(1.70
)
  
$
-
    
$
(1.70
)
 
 
  
Three months ended March 31, 2021
    
Six months ended June 30, 2021
  
 
  
As Previously
Reported
    
Adjustments
    
As Restated
    
As Previously
Reported
    
Adjustments
    
As Restated
  
 
  
(in thousands, except per share data)
    
(in thousands, except per share data)
  
Consolidated Statement of Cash Flows
  
(unaudited)
    
(unaudited)
  
 
                                    
Net loss
  
$
(17,702,000
)
  
$
(820,000
)
  
$
(18,522,000
)
  
$
(27,787,000
)
  
$
(820,000
)
  
$
(28,607,000
)
Change in fair value of contingent consideration
  
$
(820,000
)
  
$
820,000
    
$
-
    
$
(820,000
)
  
$
820,000
    
$
-
  
 
 
  
Nine months ended September 30, 2021
  
 
  
As Previously
Reported
    
Adjustments
    
As Restated
  
 
  
(in thousands, except per share data)
  
Consolidated Statement of Cash Flows
  
(unaudited)
  
 
                  
Net loss
  
$
(113,842,000
)
  
$
(750,000
)
  
$
(114,592,000
)
Change in fair value of contingent consideration
  
$
(750,000
)
  
$
750,000
    
$
-